Abstract
Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntingtons disease, amyotrophic lateral sclerosis and Parkinsons disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to various clinical trials. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline as an open-label adjunct to antipsychotic medication to patients with schizophrenia. The results of this trial suggested that minocycline might be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for “boosting” antipsychotic efficacy and for treating schizophrenia. The present review summarizes the available data supporting the clinical testing of minocycline for patients with schizophrenia. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy.
Keywords: Minocycline, schizophrenia, apoptosis, inflammation
CNS & Neurological Disorders - Drug Targets
Title: Clinical Potential of Minocycline for Schizophrenia
Volume: 7 Issue: 4
Author(s): Tsuyoshi Miyaoka
Affiliation:
Keywords: Minocycline, schizophrenia, apoptosis, inflammation
Abstract: Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntingtons disease, amyotrophic lateral sclerosis and Parkinsons disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to various clinical trials. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline as an open-label adjunct to antipsychotic medication to patients with schizophrenia. The results of this trial suggested that minocycline might be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for “boosting” antipsychotic efficacy and for treating schizophrenia. The present review summarizes the available data supporting the clinical testing of minocycline for patients with schizophrenia. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy.
Export Options
About this article
Cite this article as:
Miyaoka Tsuyoshi, Clinical Potential of Minocycline for Schizophrenia, CNS & Neurological Disorders - Drug Targets 2008; 7 (4) . https://dx.doi.org/10.2174/187152708786441858
DOI https://dx.doi.org/10.2174/187152708786441858 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microencapsulation: The Emerging Role of Microfluidics
Micro and Nanosystems Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening Applying Knowledge of Enzyme Biochemistry to the Prediction of Functional Sites for Aiding Drug Discovery
Current Topics in Medicinal Chemistry Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Versatile Functions of Heat Shock Factors: It is Not All About Stress
Current Immunology Reviews (Discontinued) Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Role of Neural Stem Cells in Neurodegenerative Diseases:From the Molecule and Cell to the Clinic (Guest Editor: Oscar Gonzalez-Perez)]
Current Signal Transduction Therapy Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview
Current Drug Research Reviews Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Denouement of Chemicals on Amyotrophic Lateral Sclerosis: Is Green Chemistry the Answer
Medicinal Chemistry The Prokaryotic FAD Synthetase Family: A Potential Drug Target
Current Pharmaceutical Design Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening